ANAPTYSBIO, INC (ANAB)
D
Pipeline Grade
Financial Position (from SEC Filings)
$248.5M
Cash & Equivalents
$25.9M
Quarterly Burn Rate
29 mo
Est. Cash Runway
$1,966M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-12 | Pdufa | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06041269 | A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) | PHASE2 | Active Not Recruiting | 420 |
| NCT06127043 | A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) | PHASE2 | Active Not Recruiting | 132 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.